Degarelix for treating advanced hormone-sensitive prostate cancer

about

Degarelix for treating advanced hormone-sensitive prostate cancer

Item

http://www.wikidata.org/entity/Q57776096

description

im Februar 2017 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована в лютому 2017

@uk

name

Degarelix for treating advanced hormone-sensitive prostate cancer

@en

Degarelix for treating advanced hormone-sensitive prostate cancer

@nl

type

Item

label

Degarelix for treating advanced hormone-sensitive prostate cancer

@en

Degarelix for treating advanced hormone-sensitive prostate cancer

@nl

prefLabel

Degarelix for treating advanced hormone-sensitive prostate cancer

@en

Degarelix for treating advanced hormone-sensitive prostate cancer

@nl

P1476

Degarelix for treating advanced hormone‐sensitive prostate cancer

@en

P2093

Anette Blümle

http://www.w3.org/2001/XMLSchema#string

Benjamin Mayer

http://www.w3.org/2001/XMLSchema#string

Christine Schmucker

http://www.w3.org/2001/XMLSchema#string

Frank Kunath

http://www.w3.org/2001/XMLSchema#string

Friedemann Zengerling

http://www.w3.org/2001/XMLSchema#string

Joachim J Jakob

http://www.w3.org/2001/XMLSchema#string

Joerg J Meerpohl

http://www.w3.org/2001/XMLSchema#string

Stefanie Schmidt

http://www.w3.org/2001/XMLSchema#string

P2860

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer

What is "quality of evidence" and why is it important to clinicians?

Measuring inconsistency in meta-analyses

Quantifying heterogeneity in a meta-analysis

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.

Effect of reporting bias on meta-analyses of drug trials: reanalysis of meta-analyses.

Androgen deprivation and antagonism in the treatment of advanced prostatic carcinoma.

Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.

P31

scholarly article

P356

10.1002/14651858.CD012548

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

2017

http://www.w3.org/2001/XMLSchema#string

P50

Joerg J Meerpohl

P577

2017-02-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P932

6464394

http://www.w3.org/2001/XMLSchema#string